An interventional study of small-quantity lipid-based nutrient supplements (SQ-LNS) in Child Malnutrition, sponsored by Boston University Charles River Campus. Recruiting at 1 site in Ghana. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Boston University Charles River Campus · Not applicable, Interventional, and Health services research
This cluster-randomized crossover trial evaluates whether the packaging format of small-quantity lipid-based nutrient supplements (SQ-LNS) affects caregiver adherence and acceptability when SQ-LNS are delivered through routine growth monitoring services in Northern Ghana. SQ-LNS are a proven intervention for reducing child malnutrition, but packaging format may affect how caregivers store, dispense, and use the product, and it also drives cost and distribution logistics. Up to sixteen health facilities participating in growth monitoring services each deliver both formats: a 1-day sachet (20 g daily) and a 7-day resealable pouch (140 g weekly), with the order of delivery randomized at facility level. Each format is delivered for one month before crossover, and caregivers receive a 28-day supply totaling 560 g in each period regardless of format. The primary outcome is adherence, measured by weighing SQ-LNS returned unconsumed and expressed as the percentage of dispensed product consumed. The trial tests whether adherence with the 7-day pouch is non-inferior to adherence with 1-day sachets, using a margin of 5.0 percentage points. Secondary outcomes include caregiver acceptability and preference, observed dispensing accuracy and package opening, and qualitative assessment of implementation facilitators and barriers. This implementation research study uses a convergent mixed-methods design, integrating quantitative adherence and acceptability data with in-depth interviews and structured observations to inform real-world program implementation. Findings will guide policy and program decisions for integrating SQ-LNS into child health platforms in Ghana and other low-resource settings.
Background and Rationale: Small-quantity lipid-based nutrient supplements (SQ-LNS) have demonstrated effectiveness in reducing child undernutrition, including stunting, wasting, and anemia, particularly among children 6-24 months of age in low- and middle-income countries. Despite strong evidence, uptake and adherence in real-world settings remain suboptimal. Packaging format may influence how caregivers understand, use, and integrate SQ-LNS into daily routines, and it also determines packaging cost and distribution burden.
Study Objectives: Primary Objective: To determine whether adherence to SQ-LNS delivered in 7-day resealable pouches is non-inferior to adherence to SQ-LNS delivered in 1-day sachets. Secondary Objectives: To assess caregiver acceptability, preferences, ease of use, and perceptions of both packaging formats; to assess observed usability at the point of dispensing; and to explore implementation facilitators and barriers to effective delivery and use of SQ-LNS within growth monitoring and promotion programs.
Study Design: This is a cluster-randomized, two-period crossover trial embedded within routine child health services at up to 16 public health facilities in the Kumbungu and Tolon districts of Northern Ghana. The trial follows a convergent mixed-methods implementation research design. Clusters are health facilities, each randomized to one of two packaging sequences. Each facility delivers one packaging format for one month, then switches to the alternate format for a second month. Participants are caregivers of children aged 6-24 months attending growth monitoring and promotion (GMP) services during the intervention periods.
Randomization: Facilities are matched by facility type (hospital, health centre, or CHPS compound), location, and average monthly GMP attendance, then randomized to one of two sequences: Sequence A, 1-day sachet followed by 7-day pouch; Sequence B, 7-day pouch followed by 1-day sachet. Randomization is at facility level and is unblinded.
Sample Size: The primary comparison is a non-inferiority test with a pre-specified margin of 5.0 percentage points of adherence. Assuming a within-subject adherence standard deviation of 20%, a within-subject correlation of 0.60, a one-sided significance level of 0.025, and 80% power, the primary comparison is powered at over 99% at the planned sample of 505 caregiver-child dyads. The enrollment target of 505 is set by the precision required for the caregiver-level acceptability and preference outcomes, estimated to a 95% confidence interval half-width of 5 percentage points, which requires 385 participants with complete endline data and approximately 480 enrolled after allowing for 20% loss to follow-up. Dyads are allocated across facilities in proportion to average monthly GMP attendance rather than equally, and are enrolled consecutively during routine GMP sessions until each facility's target is reached.
Outcomes: The primary outcome is weight-based adherence, calculated as 100 x (grams dispensed - grams returned unconsumed) / grams dispensed, net of packaging tare, collected for every enrolled dyad in each period. A weight-based definition is used because the 7-day pouch has no countable dose units, making weight the only metric measurable identically in both arms. Count-based consumption in the sachet arm and self-reported adherence are retained as supportive measures. Secondary outcomes include caregiver acceptability and preference, dispensing accuracy within 2 g of the 20 g target, package opening without a tool or assistance, and qualitative themes relating to packaging, feeding practices, and caregiver experience.
Data Collection: Quantitative data are collected through caregiver surveys at baseline, midline, and endline, and through weighing of returned product. Returned product is weighed at the first contact point that reaches the caregiver, following a fixed sequence: the next scheduled GMP clinic visit; if not captured there, a community outreach growth-monitoring event; and if still not captured, a home visit. Usability is assessed in two components: a brief facility-based observation of package opening and dose dispensing for all dyads at midline and endline, and a home observation of feeding, storage, and household environment for a randomly selected sub-sample of approximately 35 dyads stratified by facility type. Routine growth-monitoring measurements are abstracted from the child's Maternal and Child Health Record Book and from clinic registers; no anthropometric measurements are taken by study staff. Qualitative data are collected after the second crossover period through approximately 20-22 in-depth interviews with caregivers, frontline health workers, and program managers, and up to 8 focus group discussions with caregivers who completed both phases.
Analysis Plan: The primary outcome is analyzed as a continuous variable using a linear mixed model with fixed effects for packaging format, period, and sequence, and random intercepts for child and facility. Non-inferiority of the 7-day pouch to the 1-day sachet is concluded if the lower bound of the two-sided 95% confidence interval for the mean difference in adherence lies above -5.0 percentage points. The analysis is conducted in both per-protocol and intention-to-treat populations, with non-inferiority required in both, and period and carryover effects assessed. The intention-to-treat analysis uses multiple imputation as the primary approach, with a conservative sensitivity analysis and a tipping-point analysis. Secondary outcomes are analyzed using linear mixed models and standard two-sided comparisons; the non-inferiority framing applies only to the primary adherence outcome. Pre-specified subgroup analyses examine variation by facility type, socioeconomic status, and caregiver education. Qualitative data are coded and analyzed using thematic content analysis in NVivo, with codes developed both deductively from study objectives and inductively from emerging data. Quantitative and qualitative findings are triangulated to inform implementation recommendations.
Ethical Considerations: The study has been approved by the Boston University Charles River Campus IRB (protocol 8287E) and by the Ghana Health Service Ethics Review Committee (GHS ERC 006/12/25). Written informed consent is obtained from all participating caregivers before any study activity. The study poses minimal risk and is embedded in routine health services.
Dissemination: Findings will be shared with the Ghana Health Service, implementing partners, and international stakeholders, and will be submitted for publication in peer-reviewed journals.
167 studies on the registry are indexed under Child Nutrition Disorders; 36 are open to participants now.
This study's planned enrollment of 505 is above the median of 402 across 132 interventional studies indexed under Child Nutrition Disorders.
Browse Child Nutrition Disorders studies →Boston University Charles River Campus is the lead sponsor of 159 studies on the registry; 33 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 9 (64%) have results posted.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Oct 1, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Caregivers at facilities randomized to this sequence receive SQ-LNS in 1-day 20 g sachets (28 sachets, 560 g) during the first month, then 7-day 140 g resealable pouches (4 pouches, 560 g) during the second month.
Dietary Supplement: small-quantity lipid-based nutrient supplements (SQ-LNS)
Caregivers at facilities randomized to this sequence receive SQ-LNS in 7-day 140 g resealable pouches (4 pouches, 560 g) during the first month, then 1-day 20 g sachets (28 sachets, 560 g) during the second month.
Dietary Supplement: small-quantity lipid-based nutrient supplements (SQ-LNS)
Small-quantity lipid-based nutrient supplements are delivered through routine growth monitoring and promotion services in two packaging formats: 1-day 20 g sachets (20DS) and 7-day 140 g resealable pouches (7DRP). Every caregiver receives both formats, one per month, in the order determined by their facility's randomized sequence. In each period the caregiver receives a 28-day supply totaling 560 g.
Adherence to SQ-LNS, measured as the percentage of dispensed product consumed
Weight-based adherence, calculated as 100 × (grams of SQ-LNS dispensed - grams of SQ-LNS returned unconsumed) / grams of SQ-LNS dispensed, with returned product weighed net of packaging tare. Participants in both arms receive a 28-day supply totaling 560 g per period (28 × 20 g sachets in the 1-day sachet arm; 4 × 140 g resealable pouches in the 7-day pouch arm). Returned product is weighed at the first contact point reached, following a fixed sequence: the next scheduled growth monitoring clinic visit, then a community outreach growth monitoring event, then a home visit. The 7-day resealable pouch is assessed for non-inferiority to the 1-day sachet using a non-inferiority margin of 5.0 percentage points.
Time frame: Measured twice per participant: End of each one-month packaging period (Period 1 and Period 2)
Caregiver acceptability/usability
Caregiver acceptability/usability will be defined as a composite score (Likert-scaled) capturing acceptability, preference, usability, and ease of administration of the SQ-LNS packaging
Time frame: Measured twice per participant: at the end of the first 1-month phase and at the end of the second 1-month phase
Caregiver experience with SQ-LNS
Qualitative assessment of caregiver experience with SQ-LNS, including perceptions of packaging, feeding practices, and overall acceptability, collected through semi-structured interviews and analyzed using thematic content analysis.
Time frame: At the end of each 1-month crossover period (following each intervention phase)
Dispensing accuracy, measured as the percentage of caregivers dispensing a single day's dose within ±2 g of the 20 g target
At a brief facility-based observation, the caregiver opens the package and dispenses one day's dose into a tared container, which the enumerator weighs. Accuracy is recorded as whether the dispensed dose falls within ±2 g of the 20 g target.
Time frame: at the end of the first 1-month phase and at the end of the second 1-month phase
Percentage of caregivers opening the package without a tool or assistance
At the same facility-based observation, the enumerator records whether the caregiver opens the package without using a tool and without assistance.
Time frame: at the end of the first 1-month phase and at the end of the second 1-month phase
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boston University Charles River Campus →